Urologix signs deal to sell Prostiva RF therapy system for BPH

Urologix ($ULGX) has inked an exclusive worldwide license for the Prostiva RF therapy system from Medtronic ($MDT). The system is a transurethral needle ablation device that is 510(k) cleared for the treatment of BPH. The license agreement is for a 10-year term and includes the rights to manufacture and market the Prostiva product line for an upfront license fee and ongoing royalties. Urologix release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.